Key Highlights
- Precigen shares are trading down 22.41% at $5.38, against a previous close of $6.94.
- Papzimeos now faces its first direct competitor in recurrent respiratory papillomatosis.
- Third-quarter results are due Wednesday, with consensus Revenue of $72 million to $75 million.
Precigen (NASDAQ:PGEN) shares are trading down 22.41% at $5.38, against a previous close of $6.94, after the FDA granted Accelerated Approval to Inovio's (NASDAQ:INO) VOCERYQ for recurrent respiratory papillomatosis, the condition treated by Precigen's only marketed drug, Papzimeos. Volume is heavy at about 12.09 million shares, roughly double the average, and the broader healthcare sector is holding steady.
Precigen is a Germantown, Maryland-based commercial-stage biopharmaceutical company that develops gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. Papzimeos, known generically as zopapogene imadenovec-drba, is an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis, built on the AdenoVerse platform, which the FDA has granted platform technology designation. The company has about 160 employees.
A First Direct Competitor
Papzimeos had the market to itself until now. Inovio's VOCERYQ received accelerated approval late on Friday for the same condition, and Inovio expects to ship it in about 60 days. Market commentators note that Papzimeos produced stronger surgery-free data, 51% against 27% for VOCERYQ, though the figures come from separate trials and are not a head-to-head comparison.
Inovio estimates at least 25,000 patients are living with recurrent respiratory papillomatosis in the United States, a patient pool that both companies are now addressing.
Precigen also holds a head start. Papzimeos has been on the market since August 2025 and has payer coverage of about 315 million lives. Even so, analysts say a competitor adds uncertainty to long-term revenue models, and some say the selloff looks like an overreaction.
Commercial Momentum Before the Approval
Papzimeos is Precigen's first commercial product, and it generated product revenue of $53.1 million in the second quarter of 2026. The company reached quarterly profitability and expects to reach Cash Flow break-even by the end of 2026. The stock has a forward price-to-earnings ratio of 7.90 and trailing Earnings per share of negative $1.10.
Precigen's pipeline includes PRGN-2009 for HPV-related cancers and UltraCAR-T programs, and it draws on other proprietary technologies, including UltraVector, Sleeping Beauty, RheoSwitch and ActoBiotics. The company was formerly known as Intrexon.
Third-Quarter Report and What to Watch
Precigen reports third-quarter results on Wednesday, with consensus revenue of roughly $72 million to $75 million. Investors will look there for evidence of Demand for Papzimeos and for management's response to the new entrant, including how it describes payer coverage, treatment centers and patient flow.
The shares trade within a 52-week range of $3.04 to $8.98, so the decline takes them back toward the lower half of that range. The main questions now are how quickly Inovio can reach patients after its launch plans in the first quarter of 2027, how physicians weigh the two therapies and whether Precigen's lead in coverage and time on the market holds. Precigen's results on Wednesday will be the first read on whether prescribing trends have changed.






Please wait processing your request...